BioMarin Pharmaceutical | BMRN - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Bayer EUR -1.16B 735M 2025-09
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 343.6M 46.34M 2026-03
Insmed USD -326.93M 41.77M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
Moderna USD -799M 612M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.33B 32.2M 2025-12